UNICREDIT BANK/CALL/AMGEN/400/0.1/18.12.24 | Real-time BOERSE MUENCHEN 02:01:16 2024-05-30 am EDT | ||
| 0.28 EUR | 0.00% |
|
| Current month | +100.00% | ||
| 1 month | +115.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-30 | 0.28 | 0.00% |
| 24-05-29 | 0.28 | -9.68% |
| 24-05-28 | 0.31 | -13.89% |
| 24-05-27 | 0.36 | -2.70% |
| 24-05-24 | 0.37 | -5.13% |
Real-time BOERSE MUENCHEN
Last update May 30, 2024 at 02:01 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD1QYZ |
| ISIN | DE000HD1QYZ8 |
| Date issued | 2024-01-08 |
| Strike | 400 $ |
| Maturity | 2024-12-18 (203 Days) |
| Parity | 10 : 1 |
| Emission price | 0.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.95 € |
|---|---|
| Lowest since issue | 0.017 € |
| Spread | 0.16 € |
| Spread % | 48.48% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
296.4
USD
Average target price
316.3
USD
Spread / Average Target
+6.72%
- Stock Market
- Warrants
- Warrant
